Hypericum perforatum: A 'modern' herbal antidepressant - Pharmacokinetics of active ingredients

Clinical Pharmacokinetics

Volumn 45, Issue 5, 2006, Pages 449-468

  Wurglics, Mario ^a,b   Schubert Zsilavecz, Manfred ^a  

^a GOETHE UNIVERSITY   (Germany)

^b ZAFES   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CYCLOSPORIN A; DIGOXIN; ETHINYLESTRADIOL; FEXOFENADINE; FLAVONOID; FLAVONOL DERIVATIVE; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; HYPERIN; IMMUNOSUPPRESSIVE AGENT; ISOQUERCITRIN; LAIF; NAPHTHODIANTHRONE DERIVATIVE; ORAL CONTRACEPTIVE AGENT; PHLOROGLUCINOL DERIVATIVE; PROANTHOCYANIDIN DERIVATIVE; PROCYANIDIN DERIVATIVE; PROTEINASE INHIBITOR; PSEUDOHYPERICIN; QUERCETIN; QUERCITRIN; RUTOSIDE; STW 3; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; WS 5572; XANTHONE DERIVATIVE;

BINDING SITE; BLEEDING; BRAIN; BRAIN CORTEX; BREAKTHROUGH BLEEDING; CARDIOVASCULAR DISEASE; CHRONIC VEIN INSUFFICIENCY; CLINICAL TRIAL; DEPRESSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; HERBAL MEDICINE; HUMAN; HYPERICUM PERFORATUM; IN VITRO STUDY; MEMBRANE FLUIDITY; NERVE CELL MEMBRANE; NEUROTRANSMITTER UPTAKE; NONHUMAN; PHOTOTOXICITY; PRIORITY JOURNAL; REVIEW; RODENT; SKIN IRRITATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIDEPRESSIVE AGENTS; BICYCLO COMPOUNDS; CLINICAL TRIALS; DEPRESSION; FLAVONOIDS; HUMANS; HYPERICUM; PERYLENE; PHLOROGLUCINOL; PHYTOTHERAPY; PLANT EXTRACTS; TERPENES;

EID: 33646124719     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200645050-00002     Document Type: Review

References (130)

1. WHO. Depression: what is depression [online]? Available from URL: http://www.who.int/mental_health/management/depression/definition/en/ [Accessed 2006 Feb 28]
2. Ayuso-Mateos JL, Vazquez-Barquero JL, Dowrick C, et al. Depressive disorders in Europe: prevalence figures from the ODIN study. Br J Psychiatry 2001; 179: 308-16
3. Hale AS. ABC of mental health: depression. BMJ 1997; 315 (7099): 43-6
4. Thomas CM, Morris S. Cost of depression among adults in England in 2000. Br J Psychiatry Suppl 2003; 183: 514-9
5. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51 (1): 8-19
6. Lepine JP, Gastpar M, Mendlewicz J, et al. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 1997; 12 (1): 19-29
7. Richelson E. Treatment of acute depression. Psychiatr Clin North Am 1993; 16 (3): 461-78
8. Conti DJ, Burton WN. The economic impact of depression in a workplace. J Occup Med 1994; 36 (9): 983-8
9. Richelson E. Pharmacology of antidepressants. Mayo Clin Proc 2001; 76: 511-27
10. Müller WE. St. John's Wort and its active principles in depression and anxiety. Basel: Birkhäuser, 2005
11. Kommission E. Monographie: Hyperici herba (Johanniskraut). Bundesanzeiger 1984: 228
12. Kasper S. Hypericum perforatum: a review of clinical studies. Pharmacopsychiatry 2001; 34 Suppl. 1: S51-5
13. Berner M, Riemann D, Berger M. The Efficacy of SJW extracts with more than 1% or less than 0.5% hyperforin content compared to placebo in the treatment of major depression [abstract]. Eur Arch Psychiatry Clin Neurosci 2002; 252 Suppl. 1: 56
14. Laakmann G, Schule C, Baghai T, et al. St. John's Wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 1998; 31 Suppl. 1: 54-9
15. Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St John's Wort in major depression: a randomized controlled trial. JAMA 2001; 285 (15): 1978-86
16. Linde K, Berner M, Egger M, et al. St John's Wort for depression: meta-analysis of randomised controlled trials. Br J Psychiatry 2005; 186: 99-107
17. Schwabe U, Paffrath D. Arzneiverordnungs report 2003. Berlin: Springer-Verlag, 2004
18. Capasso F, Gaginella TS, Grandolini G, et al. Phytotherapy: a quick reference to herbal medicine. Berlin: Springer-Verlag, 2003
19. St. John's Wort. European Pharmacopoeia 2003; 4 Suppl. 4.5: 2157-8
20. European Medicines Agency. Guideline on quality of herbal medicinal products/traditional herbal medicinal products [online]. Available from URL: http://www.emea.eu.int/pdfs/human/qwp/281900en.pdf [Accessed 2006 Feb 28]
21. Suzuki O, Katsumata Y, Oya M, et al. Inhibition of monoamine oxidase by hypericin. Planta Medica 1984; 50 (3): 272-4
22. Nöldner M, Schotz K. Rutin is essential for the antidepressant activity of Hypericum perforatum extracts in the forced swimming test. Planta Medica 2002; 68 (7): 577-80
23. Melzer R, Fricke U, Holzl J. Vasoactive properties of procyanidins from Hypericum perforatum L. in isolated porcine coronary arteries. Arzneimittel Forschung 1991; 41 (5): 481-3
24. Barnes J, Anderson LA, Phillipson JD. St John's Wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol 2001; 53 (5): 583-600
25. Gambarana C, Tolu PL, Masi F, et al. A study of the antidepressant activity of Hypericum perforatum on animal models. Pharmacopsychiatry 2001; 34 Suppl. 1: S42-4
26. Schulte-Lobbert S, Holoubek G, Muller WE, et al. Comparison of the synaptosomal uptake inhibition of serotonin by St John's Wort products. J Pharm Pharmacol 2004; 56 (6): 813-8
27. Muller WE, Rolli M, Schafer C, et al. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 1997; 30 Suppl. 2: 102-7
28. Chatterjee SS, Bhattacharya SK, Wonnemann M, et al. Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci 1998; 63 (6): 499-510
29. Jensen AG, Hansen SH, Nielsen EO. Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity. Life Sci 2001; 68 (14): 1593-605
30. Muller WE, Singer A, Wonnemann M. Hyperforin: antidepressant activity by a novel mechanism of action. Pharmacopsychiatry 2001; 34 Suppl. 1: S98-102
31. +1. J Pharmacol Exp Ther 1999; 290 (3): 1363-8
32. Wonnemann M, Singer A, Muller WE. Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St. John's Wort: the role of amiloride sensitive sodium conductive pathways. Neuropsychopharmacology 2000; 23 (2): 188-97
33. Gobbi M, Valle FD, Ciapparelli C, et al. Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex. Naunyn Schmiedebergs Arch Pharmacol 1999; 360 (3): 262-9
34. Gobbi M, Moia M, Pirona L, et al. In vitro binding studies with two Hypericum perforatum extracts hyperforin, hypericin and biapigenin on 5-HT6, 5-HT7, GABA (A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters. Pharmacopsychiatry 2001; 34 Suppl. 1: S45-8
35. Roz N, Rehavi M. Hyperforin inhibits vesicular uptake of monoamines by dissipating pH gradient across synaptic vesicle membrane. Life Sci 2003; 73 (4): 461-70
36. Roz N, Mazur Y, Hirshfeld A, et al. Inhibition of vesicular uptake of monoamines by hyperforin. Life Sci 2002; 71 (19): 2227-37
37. Eckert GP, Keller JH, Jourdan C, et al. Hyperforin modifies neuronal membrane properties in vitro. Neurosci Lett 2004; 367 (2): 139-43
38. Treiber K, Singer A, Müller WE. Activation of nonselective cation channels by hyperforin: a novel mechanism of antidepressant activity [abstract]. Soc Neurosci 2003; 29: 851
39. Calapai G, Crupi A, Firenzuoli F, et al. Effects of Hypericum perforatum on levels of 5-hydroxytryptamine, noradrenaline and dopamine in the cortex, diencephalon and brainstem of the rat. J Pharm Pharmacol 1999; 51 (6): 723-8
40. Yu PH. Effect of the Hypericum perforatum extract on serotonin turnover in the mouse brain. Pharmacopsychiatry 2000; 33 (2): 60-5
41. Serdarevic N, Eckert GP, Muller WE. The effects of extracts from St. John's Wort and Kava Kava on brain neurotransmitter levels in the mouse. Pharmacopsychiatry 2001; 34 Suppl. 1: S134-6
42. Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John's Wort. Lancet 2000; 355 (9203): 548-9
43. Mathijssen RH, Verweij J, de Bruijn P, et al. Effects of St. John's Wort on irinotecan metabolism. J Natl Cancer Inst 2002; 94 (16): 1247-9
44. Fugh-Berman A. Herb-drug interactions. Lancet 2000; 355 (9198): 134-8
45. Ernst E. St John's Wort supplements endanger the success of organ transplantation. Arch Surg 2002; 137 (3): 316-9
46. Ernst E. Second thoughts about safety of St John's Wort. Lancet 1999; 354 (9195): 2014-6
47. Ernst E, Rand JI, Barnes J, et al. Adverse effects profile of the herbal antidepressant St. John's Wort (Hypericum perforatum L.). Eur J Clin Pharmacol 1998; 54 (8): 589-94
48. Mai I, Bauer S, Perloff ES, et al. Hyperforin content determines the magnitude of the St John's Wort-cyclosporine drug interaction. Clin Pharmacol Ther 2004; 76 (4): 330-40
49. Wentworth JM, Agostini M, Love J, et al. St John's Wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000; 166 (3): R11-6
50. Watkins RE, Maglich JM, Moore LB, et al. 2.1 A crystal structure of human PXR in complex with the St. John's Wort compound hyperforin. Biochemistry 2003; 42 (6): 1430-8
51. Moore LB, Goodwin B, Jones SA, et al. St. John's Wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 2000; 97 (13): 7500-2
52. Nebel A, Schneider BJ, Baker RK, et al. Potential metabolic interaction between St. John's Wort and theophylline. Ann Pharmacother 1999; 33 (4): 502
53. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73 (1): 67-74
54. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's Wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003; 290 (11): 1500-4
55. Izzo AA. Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther 2004; 42 (3): 139-48
56. Komoroski BJ, Zhang S, Cai H, et al. Induction and inhibition of cytochromes P450 by the St. John's Wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 2004; 32 (5): 512-8
57. Schwarz UI, Buschel B, Kirch W. Unwanted pregnancy on self-medication with St John's Wort despite hormonal contraception. Br J Clin Pharmacol 2003; 55 (1): 112-3
58. Henderson L, Yue QY, Bergquist C, et al. St John's Wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002; 54 (4): 349-56
59. Pfrunder A, Schiesser M, Gerber S, et al. Interaction of St John's Wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol 2003; 56 (6): 683-90
60. Hall SD, Wang Z, Huang SM, et al. The interaction between St John's Wort and an oral contraceptive. Clin Pharmacol Ther 2003; 74 (6): 525-35
61. Johne A, Brockmoller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's Wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66 (4): 338-45
62. Wang EJ, Barecki-Roach M, Johnson WW. Quantitative characterization of direct P-glycoprotein inhibition by St John's Wort constituents hypericin and hyperforin. J Pharm Pharmacol 2004; 56 (1): 123-8
63. Wang Z, Hamman MA, Huang SM, et al. Effect of St John's Wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002; 71 (6): 414-20
64. Bodo A, Bakos E, Szeri F, et al. The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett 2003; 140-141: 133-43
65. Durr D, Stieger B, Kullak-Ublick GA, et al. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68 (6): 598-604
66. Mannel M. Drug interactions with St John's Wort: mechanisms and clinical implications. Drug Saf 2004; 27 (11): 773-97
67. Nahrstedt A, Butterweck V. Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry 1997; 30 Suppl. 2: 129-34
68. Schulte-Lobbert S, Westerhoff K, Wilke A, et al. Development of a high-performance-liquid-chromatographic method for the determination of biapigenin in biorelevant media. J Pharm Biomed Anal 2003; 33 (1): 53-60
69. Hertog MG, Feskens EJ, Kromhout D. Antioxidant flavonols and coronary heart disease risk. Lancet 1997; 349 (9053): 699
70. Yochum L, Kushi LH, Meyer K, et al. Dietary flavonoid intake and risk of cardiovascular disease in postmenopausal women [published erratum appears in Am J Epidemiol 1999 Aug 15; 150 (4): 432]. Am J Epidemiol 1999; 149 (10): 943-9
71. Kiesewetter H, Koscielny J, Kalus U, et al. Efficacy of orally administered extract of red vine leaf AS 195 (folia vitis viniferae) in chronic venous insufficiency (stages I-II): a randomized, double-blind, placebo-controlled trial. Arzneimittel Forschung 2000; 50 (2): 109-17
72. Ihme N, Kiesewetter H, Jung F, et al. Leg oedema protection from a buckwheat herb tea in patients with chronic venous insufficiency: a single-centre, randomised, double-blind, placebo-controlled clinical trial. Eur J Clin Pharmacol 1996; 50 (6): 443-7
73. Demisch L, Hölzl J, Gollnik B, et al. Identification of selective MAO-Typ A inhibition of Hypericum perforatum L [abstract]. Pharmacopsychiatry 1989; 22: 194
74. Thiede HM, Walper A. Inhibition of MAO and COMT by hypericum extracts and hypericin. J Geriatr Psychiatry Neurol 1994; 7 Suppl. 1: S54-6
75. Cracchiolo C. Pharmacology of St. John's Wort: botanical and chemical aspects. Sci Rev Alt Med 1998; 2: 29-35
76. Cott JM. In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry 1997; 30 Suppl. 2: 108-12
77. Butterweck V, Nahrstedt A, Evans J, et al. In vitro receptor screening of pure constituents of St. John's Wort reveals novel interactions with a number of GPCRs. Psychopharmacology (Berl) 2002; 162 (2): 193-202
78. Butterweck V, Jurgenliemk G, Nahrstedt A, et al. Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test. Planta Med 2000; 66 (1): 3-6
79. Porsolt RD. Animal model of depression. Biomedicine 1979; 30 (3): 139-40
80. Nöldner M. Behandlung von depressiven Patienten in der täglichen Praxis - Stellenwert von Johanniskraut. Neu-Isenburg: LinguaMed Verlags-GmbH, 2001
81. Butterweck V, Korte B, Winterhoff H. Pharmacological and endocrine effects of Hypericum perforatum and hypericin after repeated treatment. Pharmacopsychiatry 2001; 34 Suppl. 1: S2-7
82. Butterweck V, Hegger M, Winterhoff H. Flavonoids of St. John's Wort reduce HPA axis function in the rat. Planta Med 2004; 70 (10): 1008-11
83. Rubin RT, Phillips JJ, McCracken JT, et al. Adrenal gland volume in major depression: relationship to basal and stimulated pituitary-adrenal cortical axis function. Biol Psychiatry 1996; 40 (2): 89-97
84. Rubin RT, Phillips JJ, Sadow TF, et al. Adrenal gland volume in major depression. Increase during the depressive episode and decrease with successful treatment. Arch Gen Psychiatry 1995; 52 (3): 213-8
85. Holsboer F, Benkert O. Neuroendocrinologic and endocrinologic research in depressive patients [in German]. Nervenarzt 1985; 56 (1): 1-11
86. Holsboer F, Liebl R, Hofschuster E. Repeated dexamethasone suppression test during depressive illness: normalisation of test result compared with clinical improvement. J Affect Disord 1982; 4 (2): 93-101
87. Baureithel KH, Buter KB, Engesser A, et al. Inhibition of benzodiazepine binding in vitro by amentoflavone, a constituent of various species of Hypericum. Pharm Acta Helv 1997; 72 (3): 153-7
88. Butterweck V, Lieflander-Wulf U, Winterhoff H, et al. Plasma levels of hypericin in presence of procyanidin B2 and hyperoside: a pharmacokinetic study in rats. Planta Med 2003; 69 (3): 189-92
89. Butterweck V, Bockers T, Korte B, et al. Long-term effects of St. John's Wort and hypericin on monoamine levels in rat hypothalamus and hippocampus. Brain Res 2002; 930 (1-2): 21-9
90. Butterweck V, Winterhoff H, Herkenham M. St John's Wort, hypericin, and imipramine: a comparative analysis of mRNA levels in brain areas involved in HPA axis control following short-term and long-term administration in normal and stressed rats. Mol Psychiatry 2001; 6 (5): 547-64
91. Butterweck V, Petereit F, Winterhoff H, et al. Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test. Planta Med 1998; 64 (4): 291-4
92. Brockmöller J, Reum T, Bauer S, et al. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997; 30 Suppl. 2: 94-101
93. Agostinis P, Vantieghem A, Merlevede W, et al. Hypericin in cancer treatment: more light on the way. Int J Biochem Cell Biol 2002; 34 (3): 221-41
94. Lenard J, Rabson A, Vanderoef R. Photodynamic inactivation of infectivity of human immunodeficiency virus and other enveloped viruses using hypericin and rose bengal: inhibition of fusion and syncytia formation. Proc Natl Acad Sci U S A 1993; 90 (1): 158-62
95. Andersen DO, Weber ND, Wood SG, et al. In vitro virucidal activity of selected anthraquinones and anthraquinone derivatives. Antiviral Res 1991; 16 (2): 185-96
96. Hänsel R, Keller K, Rimpler H, et al. Hager's Handbuch der Pharmazeutischen Praxis. Berlin: Srpinger-Verlag, 1993
97. Hölzl J, Sattler S, Schütt H. Johanniskraut: eine Alternative zu synthetischen Antidepressiva? Pharmazeutische Zeitung 1994; 139: 3959-77
98. Erdelmeier CA. Hyperforin, possibly the major non-nitrogenous secondary metabolite of Hypericum perforatum L. Pharmacopsychiatry 1998; 31 Suppl. 1: 2-6
99. Ostrowski E. Untersuchung zur Analytik, 14C-Markierung und Pharmakokinetik phenolischer Inhaltsstoffe von Hypericum perforatum L. Marburg: University of Marburg, 1988
100. Biber A, Fischer H, Romer A, et al. Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. Pharmacopsychiatry 1998; 31 Suppl. 1: 36-43
101. Franklin M, Chi J, McGavin C, et al. Neuroendocrine evidence for dopaminergic actions of hypericum extract (LI 160) in healthy volunteers. Biol Psychiatry 1999; 46 (4): 581-4
102. Agrosi M, Mischiatti S, Harrasser PC, et al. Oral bioavailability of active principles from herbal products in humans: a study on Hypericum perforatum extracts using the soft gelatin capsule technology. Phytomedicine 2000; 7 (6): 455-62
103. Cui Y, Gurley B, Ang CY, et al. Determination of hyperforin in human plasma using solid-phase extraction and high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 780 (1): 129-35
104. Schulz HU, Schurer M, Bassler D, et al. Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet. Arzneimittel Forschung 2005; 55 (1): 15-22
105. Wurglics M, Westerhoff K, Kaunzinger A, et al. Batch-to-batch reproducibility of St. John's Wort preparations. Pharmacopsychiatry 2001; 34 Suppl. 1: S152-6
106. Wonnemann M, Singer A, Siebert B, et al. Evaluation of synaptosomal uptake inhibition of most relevant constituents of St. John's Wort. Pharmacopsychiatry 2001; 34 Suppl. 1: S148-51
107. Cervo L, Rozio M, Ekalle-Soppo CB, et al. Role of hyperforin in the antidepressant-like activity of Hypericum perforatum extracts. Psychopharmacology 2002; 164 (4): 423-8
108. Keller JH, Karas M, Muller WE, et al. Determination of hyperforin in mouse brain by high-performance liquid chromatography/tandem mass spectrometry. Anal Chem 2003; 75 (22): 6084-8
109. Liebes L, Mazur Y, Freeman D, et al. A method for the quantitation of hypericin, an antiviral agent, in biological fluids by high-performance liquid chromatography. Anal Biochem 1991; 195 (1): 77-85
110. Bauer S, Stormer E, Graubaum HJ, et al. Determination of hyperforin, hypericin, and pseudohypericin in human plasma using high-performance liquid chromatography analysis with fluorescence and ultraviolet detection. J Chromatogr B Biomed Sci Appl 2001; 765 (1): 29-35
111. Pirker R, Huck CW, Bonn GK. Simultaneous determination of hypericin and hyperforin in human plasma and serum using liquid-liquid extraction, high-performance liquid chromatography and liquid chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 2002; 777 (1-2): 147-53
112. Kerb R, Brockmoller J, Staffeldt B, et al. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother 1996; 40 (9): 2087-93
113. Staffeldt B, Kerb R, Brockmoller J, et al. Pharmacokinetics of hypericin and pseudohypericin after oral intake of the hypericum perforatum extract LI 160 in healthy volunteers. J Geriatr Psychiatry Neurol 1994; 7 Suppl. 1: S47-53
114. Weiser D. Pharmakokinetik von Hypericin nach der oralen Einnahme des Johanniskraut-Extrakte LI160. Nervenheilkunde 1991; 10: 318-9
115. Fox E, Murphy RF, McCully CL, et al. Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates. Cancer Chemother Pharmacol 2001; 47 (1): 41-4
116. Hollman PC, de Vries JH, van Leeuwen SD, et al. Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr 1995; 62 (6): 1276-82
117. Hollman PC, van Trijp JM, Buysman MN, et al. Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man. FEBS Lett 1997; 418 (1-2): 152-6
118. Hollman PC, Bijsman MN, van Gameren Y, et al. The sugar moiety is a major determinant of the absorption of dietary flavonoid glycosides in man. Free Radic Res 1999; 31 (6): 569-73
119. Cermak R, Landgraf S, Wolffram S. The bioavailability of quercetin in pigs depends on the glycoside moiety and on dietary factors. J Nutr 2003; 133 (9): 2802-7
120. Wolffram S, Block M, Ader P. Quercetin-3-glucoside is transported by the glucose carrier SGLT1 across the brush border membrane of rat small intestine. J Nutr 2002; 132 (4): 630-5
121. Graefe EU, Wittig J, Mueller S, et al. Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol 2001; 41 (5): 492-9
122. Day AJ, Mellon F, Barron D, et al. Human metabolism of dietary flavonoids: identification of plasma metabolites of quercetin. Free Radic Res 2001; 35 (6): 941-52
123. Ishii K, Furuta T, Kasuya Y. Determination of rutin in human plasma by high-performance liquid chromatography utilizing solid-phase extraction and ultraviolet detection. J Chromatogr B Biomed Sci Appl 2001; 759 (1): 161-8
124. Manach C, Morand C, Demigne C, et al. Bioavailability of rutin and quercetin in rats. FEBS Lett 1997; 409 (1): 12-6
125. O'Leary KA, Day AJ, Needs PW, et al. Metabolism of quercetin-7- and quercetin-3-glucuronides by an in vitro hepatic model: the role of human beta-glucuronidase, sulfotransferase, catechol-O-methyltransferase and multi-resistant protein 2 (MRP2) in flavonoid metabolism. Biochem Pharmacol 2003; 65 (3): 479-91
126. Graefe EU, Derendorf H, Veit M. Pharmacokinetics and bioavailability of the flavonol quercetin in humans. Int J Clin Pharmacol Ther 1999; 37 (5): 219-33
127. Erlund I, Kosonen T, Alfthan G, et al. Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol 2000; 56 (8): 545-53
128. Erlund I, Alfthan G, Siren H, et al. Validated method for the quantitation of quercetin from human plasma using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl 1999; 727 (1-2): 179-89
129. Juergenliemk G, Boje K, Huewel S, et al. In vitro studies indicate that miquelianin (quercetin 3-O-beta-D-glucuronopyranoside) is able to reach the CNS from the small intestine. Planta Med 2003; 69 (11): 1013-7
130. Gutmann H, Bruggisser R, Schaffner W, et al. Transport of amentoflavone across the blood-brain barrier in vitro. Planta Med 2002; 68 (9): 804-7